Cited by 137Photodynamic Therapy Research StudiesDrug Transport and Resistance MechanismsNanoplatforms for cancer theranostics

The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2

Open access
Liu, Weiguo, Baer, Maria R., Bowman, Mary Jo, Pera, Paula, Zheng, Xiang, Morgan, Janet, Pandey, Ravindra A., Oseroff, Allan R.·2007·Clinical Cancer Research

Abstract

Purpose: The ATP-binding cassette protein ABCG2 (breast cancer resistance protein) effluxes some of the photosensitizers used in photodynamic therapy (PDT) and, thus, may confer resistance to this treatment modality. Tyrosine kinase inhibitors (TKI) can block the function of ABCG2. Therefore, we tested the effects of the TKI imatinib mesylate (Gleevec) on photosensitizer accumulation and in vitro and in vivo PDT efficacy. Experimental Design: Energy-dependent photosensitizer efflux and imatinib mesylate's effects on intracellular accumulation of clinically used second- and first-generation photosensitizers were studied by flow cytometry in murine and human cells with and without ABCG2 expression. Effects of ABCG2 inhibition on PDT were examined in vitro using cell viability assays and in vivo measuring photosensitizer accumulation and time to regrowth in a RIF-1 tumor model. Results: Energy-dependent efflux of 2-(1-hexyloxethyl)-2-devinyl pyropheophorbide-a (HPPH, Photochlor), endogenous protoporphyrin IX (PpIX) synthesized from 5-aminolevulenic acid, and the benzoporphyrin derivative monoacid ring A (BPD-MA, Verteporfin) was shown in ABCG2+ cell lines, but the first-generation multimeric photosensitizer porfimer sodium (Photofrin) and a novel derivative of HPPH conjugated to galactose were minimally transported. Imatinib mesylate increased accumulation of HPPH, PpIX, and BPD-MA from 1.3- to 6-fold in ABCG2+ cells, but not in ABCG2− cells, and enhanced PDT efficacy both in vitro and in vivo. Conclusions: Second-generation clinical photosensitizers are transported out of cells by ABCG2, and this effect can be abrogated by coadministration of imatinib mesylate. By increasing intracellular photosensitizer levels in ABCG2+ tumors, imatinib mesylate or other ABCG2 transport inhibitors may enhance efficacy and selectivity of clinical PDT.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-06-1599

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Liu, W., Baer, M. R., Bowman, M. J., Pera, P., Zheng, X., Morgan, J., Pandey, R. A., & Oseroff, A. R.
Affiliations
  • 1Dermatology, Departments of
  • 2Medicine, and
  • Roswell Park Comprehensive Cancer Center (US)
Venue
Clinical Cancer Research
Published
2007-04-15
Volume
13
Issue
8
Pages
2463-2470
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2147445587
Cited by
136
References
47
Citations by year
2026: 1 · 2025: 3 · 2024: 7 · 2023: 9 · 2022: 7 · 2021: 4 · 2020: 6 · 2019: 9 · 2018: 7 · 2017: 7 · 2016: 2 · 2015: 12 · 2014: 13 · 2013: 6 · 2012: 12
FWCI
5.49
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Cheng Kung University Hospital
  • National Cancer Institute (P30 CA16056, P01 CA55791, P01CA055791, P30CA016056)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
imatinib mesylate, ABCG2, photodynamic therapy, photosensitizer accumulation, tyrosine kinase inhibitors, drug resistance, HPPH, protoporphyrin IX, verteporfin, porfimer sodium, combination therapy
MeSH terms
Imatinib Mesylate, ATP Binding Cassette Transporter, Subfamily G, Member 2, Antineoplastic Agents, Benzamides, Carcinoma, Squamous Cell, Combined Modality Therapy, Humans, Hypopharyngeal Neoplasms, Neoplasm Proteins, Photochemotherapy, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Photosensitizing Agents, ATP-Binding Cassette Transporters, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review